Cingulate Inc.
NASDAQ: CINGW0.00 n/a
+0.00%(+0.00)
Key facts
- Exchange
- NASDAQ Capital Market
- Sector
- Healthcare
- Industry
- Biotechnology
- CEO
- Shane J. Schaffer
- Employees
- 13
- Headquarters
- Kansas City, United States
- IPO year
- 2021
- Market cap
- $135.1K
- Website
- https://www.cingulate.com
Loading CINGW…
Loading profile data…Frequently asked questions about CINGW
What does Cingulate Inc. (CINGW) do?
Cingulate Inc. is a biopharmaceutical firm in the clinical development stage, dedicated to pioneering therapies for central nervous system and neurobiological conditions. Its leading investigational medicines are CTx-1301 (dexmethylphenidate) and CTx-1302 (dextroamphetamine), both designed to manage attention deficit/hyperactivity disorders (ADH...
Where does CINGW trade?
Cingulate Inc. (CINGW) trades on the NASDAQ Capital Market.
What sector is CINGW in?
Cingulate Inc. (CINGW) operates in the Healthcare sector, specifically in the Biotechnology industry.
Who is the CEO of Cingulate Inc.?
Shane J. Schaffer is the chief executive officer of Cingulate Inc. (CINGW).
Where is Cingulate Inc. headquartered?
Cingulate Inc. is headquartered in United States.
Does CINGW pay a dividend?
Cingulate Inc. (CINGW) does not currently pay a regular dividend. Check the dividends tab for any historical or special distributions.
When did CINGW go public?
Cingulate Inc. (CINGW) completed its initial public offering in 2021.